Table 1. Human brain tissue of Alzheimer's disease (AD) and control (Con) cases used in this study.
Case | Age at death (years) | Gender | PMI (h) | Braak stagea | Tangle scoresb |
---|---|---|---|---|---|
AD1c | 89 | F | 3.0 | V | 14.5 |
AD2c | 80 | F | 2.25 | VI | 14.5 |
AD3c | 85 | F | 1.66 | V | 12.0 |
AD4c | 78 | F | 1.83 | VI | 15.0 |
AD5c | 95 | F | 3.16 | VI | 10.0 |
AD6c | 86 | M | 2.25 | VI | 13.5 |
AD7c | 91 | F | 3.0 | V | 8.5 |
AD8d | 83 | F | 3.0 | VI | 12.4 |
AD9d | 74 | M | 2.75 | VI | 14.66 |
AD10d | 79 | F | 1.5 | VI | 14.66 |
AD11d | 73 | F | 2.0 | V | 15.00 |
AD12d | 81 | M | 3.0 | V | 11.00 |
AD13d | 76 | M | 2.33 | VI | 15.00 |
AD14d | 72 | M | 2.5 | VI | 15.00 |
AD15d | 74 | F | 2.83 | VI | 15.00 |
AD16d | 76 | M | 4.0 | V | 15.00 |
AD17d | 78 | M | 1.83 | VI | 15.00 |
Mean ± S.D. | 80.59 ± 6.70 | 2.52 ± 0.65 | 13.57 ± 2.05 | ||
Con1d | 85 | F | 2.75 | II | 5.0 |
Con2d | 82 | F | 2.0 | II | 4.25 |
Con3d | 70 | F | 2.0 | I | 0.00 |
Con4d | 73 | M | 2.0 | III | 2.75 |
Con5d | 78 | M | 1.66 | I | 0.00 |
Con6d | 80 | M | 3.25 | I | 2.75 |
Con7d | 80 | M | 2.16 | II | 1.00 |
Con8d | 83 | F | 3.25 | I | 0.75 |
Con9d | 82 | F | 2.25 | II | 3.50 |
Con10d | 85 | M | 2.5 | II | 4.25 |
Con11c | 85 | M | 2.5 | II | 4.25 |
Con12c | 86 | F | 2.5 | III | 5.00 |
Con13c | 81 | M | 2.75 | III | 6.41 |
Con14c | 88 | F | 3.0 | II | 2.00 |
Con15c | 90 | F | 3.0 | III | 4.50 |
Con16c | 88 | F | 3.5 | III | 2.50 |
Con17c | 88 | F | 3.0 | IV | 4.50 |
Mean ± S.D. | 82.59 ± 5.50 | 2.59 ± 0.53 | 3.14 ± 1.89 |
Abbreviation: PMI, postmortem interval.
aNeurofibrillary pathology was staged according to Braak and Braak (1995).
bTangle score was a density estimate and was designated none, sparse, moderate, or frequent (0, 1, 2 or 3 for statistics), as defined according to CERADAD criteria. Five areas (frontal, temporal, parietal, hippocampal, and entorhinal) were examined, and the scores were added up for a maximum of 15.
cCases were used for measurement of tau and TDP-43 in the frontal cortex and cerebellum.
dCases were used for tau measurement by immune-dot-blots.